PubMed Health⌕ Search

Biomedical subjects

P Krauseneck

Publications and source records attributed to P Krauseneck.

9 recordsLinked to original sources
PubMed1979

[Stroke].

Explore the source record for details and available documents.

Cerebrovascular Disorders↗
PubMed1977

[Cortical blindness, clinical, psychologic, and localizatory findings (author's transl)].

Description and evaluation of a case in which both occipital lobes of the brain and adjacent temporal and parietal areas were heavily damaged by malignant meningiomas. Loss of simple and complex visual functions resulted. During a 5-year period the clinical, neurologic, ophthalmologic, and psychologic findings could be completed by self-observation by the highly intelligent patient and compared with findings from three operations. Postmortal neuropathologic analysis showed loss of both left and right areas 17 and 18 and of right area 19. The localizations of elementary and complex visual functions in the brain are discussed.

Aged↗
PubMedDate not supplied

Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration.

Single bolus doses of glycosylated human interleukin-2 (n IL-2) in the range of 2.8 x 10(3) to 2.0 x 10(6) IU/kg were administered to anesthesized cats via the cephalic vein (n = 10) or using suboccipital puncture (n = 8). CSF (cerebrospinal fluid) and blood samples were collected by repeated puncture. The n IL-2 concentration in four cats was determined on the basis of its biologic activity using 3H-thymidine incorporation into human ConA-blasts and by radioimmunoassay. In additional experiments radioactivity was determined in cerebrospinal fluid and serum after intravenous and intrathecal (i.th.) application of 5.8 x 10(3) - 3.2 x 10(3) IU/kg of 14C-acetyl-n IL-2 in regular time intervals. CSF and serum concentration time-profiles show a biexponential decline in the plasma elimination phase with half-lives of 4 min (alpha-phase) and 90 min (beta-phase) after intravenous and 20-120 min (alpha-phase) and 2-16 hours (beta-phase) after intrathecal application. There is a trend towards longer terminal elimination half-lives with increasing doses. Interleukin-2 is able to penetrate the blood brain barrier from the circulation into the cerebrospinal fluid and vice versa. Due to a slow rate of penetration and rapid elimination from blood only traces of n IL-2 (2-8 IU/ml) are detected in CSF after i.v. injection of 2 x 10(6) IU/kg, whereas concentrations between 400 and 1600 IU/ml are maintained in CSF for several hours following i.th. administration of 2-10 x 10(5) IU/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗